Tryptase and tumor angiogenesis
Tryptases represent the most abundant constituent of human mast cells, involved in extracellular matrix degradation, contributing to wound healing and metastasis. Moreover, most recently, it has been demonstrated that tryptase is angiogenic both in vitro and in vivo. Tryptase-positive mast cell numb...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1500482/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850113390084620288 |
|---|---|
| author | Domenico Ribatti |
| author_facet | Domenico Ribatti |
| author_sort | Domenico Ribatti |
| collection | DOAJ |
| description | Tryptases represent the most abundant constituent of human mast cells, involved in extracellular matrix degradation, contributing to wound healing and metastasis. Moreover, most recently, it has been demonstrated that tryptase is angiogenic both in vitro and in vivo. Tryptase-positive mast cell number increases parallelly with increased microvascular density in both solid and hematological tumors. The objective and the scope of this review article are to emphasize the important role of tryptase as one of the principal effectors of tumor angiogenesis mediated by mast cells. In this context, tryptase inhibitors may be considered a novel therapeutic approach in cancer treatment. |
| format | Article |
| id | doaj-art-075eefc2961b41afa3acdc3153c148e1 |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-075eefc2961b41afa3acdc3153c148e12025-08-20T02:37:10ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-12-011410.3389/fonc.2024.15004821500482Tryptase and tumor angiogenesisDomenico RibattiTryptases represent the most abundant constituent of human mast cells, involved in extracellular matrix degradation, contributing to wound healing and metastasis. Moreover, most recently, it has been demonstrated that tryptase is angiogenic both in vitro and in vivo. Tryptase-positive mast cell number increases parallelly with increased microvascular density in both solid and hematological tumors. The objective and the scope of this review article are to emphasize the important role of tryptase as one of the principal effectors of tumor angiogenesis mediated by mast cells. In this context, tryptase inhibitors may be considered a novel therapeutic approach in cancer treatment.https://www.frontiersin.org/articles/10.3389/fonc.2024.1500482/fullangiogenesismast cellstryptasetumor growthproteases |
| spellingShingle | Domenico Ribatti Tryptase and tumor angiogenesis Frontiers in Oncology angiogenesis mast cells tryptase tumor growth proteases |
| title | Tryptase and tumor angiogenesis |
| title_full | Tryptase and tumor angiogenesis |
| title_fullStr | Tryptase and tumor angiogenesis |
| title_full_unstemmed | Tryptase and tumor angiogenesis |
| title_short | Tryptase and tumor angiogenesis |
| title_sort | tryptase and tumor angiogenesis |
| topic | angiogenesis mast cells tryptase tumor growth proteases |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1500482/full |
| work_keys_str_mv | AT domenicoribatti tryptaseandtumorangiogenesis |